Disparities in the Treatment of Patients With IL-2 for Metastatic Renal Cell Carcinoma

Urologic Oncology: Seminars and Original Investigations - United States
doi 10.1016/j.urolonc.2008.09.022
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients With Metastatic Renal Cell Carcinoma

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2010English

Nonablative Hematopoietic Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma

Bone Marrow Transplantation
TransplantationHematology
2002English

New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

2012English

Intravenous Interleukin-2 in Patients Over 65 With Metastatic Renal Carcinoma

British Journal of Cancer
Cancer ResearchOncology
1992English

Prognosis of Patients With Metastatic Renal Cell Carcinoma and Pancreatic Metastases

BJU International
Urology
2015English

Quality of Life of Patients With Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period With Targeted Drugs

Üroonkoloji Bülteni
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy